Skip to content

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Drug Development · The big question

Testosterone Gel Stops Dangerous Belly Fat in Older Women

Scientists find a way to stop dangerous belly fat as we age

Editorial illustration for Scientists find a way to stop dangerous belly fat as we age
Editorial illustration

Summary

As we get older, our bodies do not just gain weight. They actually change where fat is stored. Aging tends to push more fat into the abdomen, creating what is known as visceral fat. This is a dangerous type of fat that sits deep inside the body and wraps around internal organs, increasing various health risks. Researchers have recently discovered that the hormone testosterone plays a major part in this age-related change.

To see if they could stop this harmful fat buildup, scientists tested a new approach on older women who were recovering from hip fractures. They prescribed a testosterone gel to be used alongside a regular exercise routine. The results were highly encouraging. The patients who used the hormone gel and exercised successfully avoided the typical increase in dangerous visceral fat that usually follows such an injury.

Why it matters.

This discovery offers a promising new strategy for helping patients heal from major injuries while protecting their long-term health. A severe injury like a hip fracture drastically limits a person's mobility, making them highly vulnerable to sudden increases in deep belly fat. By stopping this dangerous fat accumulation, doctors might be able to help older patients avoid a cascade of secondary health problems during their recovery period.

It is important to note that these findings come with a few early-stage limitations. The current research focuses entirely on a highly specific group of older women recovering from broken hips. Additionally, the initial reports do not include exact numbers on how many people were studied or the precise measurements of fat reduction. Scientists will need to conduct broader studies to understand if this therapy could safely help the wider aging population.

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗